Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T16:36:53.002Z.
Calculation as of: 2026-10-06T16:36:53.002Z.
Quote observation: 2026-10-06T16:35:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 26b9d76e1867df839f3ea79fd47ae1c5236575fa33f8c6240ddbf9d3395e1dfe
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$34.04M
EV/FCF Ratio
N/A
TTM Avg
17.34x
3Y Avg
44.12x
5Y Avg
46.63x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Elicio Therapeutics, Inc. (ELTX) | $36.42M | N/A | N/A | N/A | N/A |
| QT Imaging Holdings, Inc. (QTI)vs › | $36.76M | N/A | N/A | N/A | N/A |
| DocGo Inc. (DCGO)vs › | $35.76M | N/A | 1.82x | 3.39x | 16.62x |
| Edesa Biotech, Inc. (EDSA)vs › | $37.33M | N/A | N/A | N/A | N/A |
| Elutia Inc (ELUT)vs › | $35.15M | N/A | N/A | N/A | N/A |
| BriaCell Therapeutics Corp. (BCTX)vs › | $35.10M | N/A | N/A | N/A | N/A |
| Incannex Healthcare Limited (IXHL)vs › | $38.04M | N/A | N/A | N/A | N/A |
| Grace Therapeutics, Inc. (GRCE)vs › | $34.50M | N/A | N/A | N/A | N/A |
| Accuray Incorporated (ARAY)vs › | $34.04M | N/A | 17.34x | 44.12x | 46.63x |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.88M | N/A | 20.47x | 71.52x | 76.62x |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
